Literature DB >> 18614761

High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE).

Alanna M Chamberlain1, Aaron R Folsom, Susan R Heckbert, Wayne D Rosamond, Mary Cushman.   

Abstract

We determined prospectively the risk of venous thromboembolism (VTE) in relation to baseline high-density lipoprotein cholesterol (HDL-c) in 19 049 participants of the Longitudinal Investigation of Thromboembolism Etiology (LITE), which was composed of 14 490 participants of the Atherosclerosis Risk in Communities (ARIC) study and 4559 participants of the Cardiovascular Health Study (CHS). In addition, we determined the risk of VTE in relation to baseline subfractions of HDL (HDL(2) and HDL(3)) and apolipoprotein A-I (apoA-I) in 14 488 participants of the ARIC study. Age-adjusted incidence rates of VTE by HDL-c quartile ranged from 1.64 to 1.91 per 1000 person-years in men and 1.40 to 1.94 per 1000 person-years in women; however, there was no apparent trend of VTE incidence across HDL-c quartiles for either sex. The multivariate adjusted hazard ratios of VTE by HDL-c quartiles (with quartile 4 as the reference) were nonsignificant for both sexes and ranged between 0.91 and 0.99 for men and 0.78 and 1.22 for women. Results did not differ in separate evaluations of idiopathic and secondary VTE. In the ARIC study, there was no trend of VTE hazard ratios across quartiles of HDL(2), HDL(3), or apoA-I. Low HDL-c does not appear to be an important VTE risk factor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18614761      PMCID: PMC2556604          DOI: 10.1182/blood-2008-05-157412

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Risk factors for venous thrombotic disease.

Authors:  F R Rosendaal
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

2.  Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol.

Authors:  G R Warnick; J Benderson; J J Albers
Journal:  Clin Chem       Date:  1982-06       Impact factor: 8.327

3.  The epidemiology of venous thromboembolism in the community.

Authors:  J A Heit; M D Silverstein; D N Mohr; T M Petterson; C M Lohse; W M O'Fallon; L J Melton
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

4.  Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology.

Authors:  Albert W Tsai; Mary Cushman; Wayne D Rosamond; Susan R Heckbert; Joseph F Polak; Aaron R Folsom
Journal:  Arch Intern Med       Date:  2002-05-27

Review 5.  Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool.

Authors:  Meyer Michel Samama; Ola E Dahl; Daniel J Quinlan; Patrick Mismetti; Nadia Rosencher
Journal:  Haematologica       Date:  2003-12       Impact factor: 9.941

6.  Serum lipid levels and the risk of venous thrombosis.

Authors:  Carine J M Doggen; Nicholas L Smith; Rozenn N Lemaitre; Susan R Heckbert; Frits R Rosendaal; Bruce M Psaty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-08-26       Impact factor: 8.311

7.  The concentrations of soluble vascular cell adhesion molecule-1 and lipids are independently associated with venous thromboembolism.

Authors:  Angel José González-Ordóñez; José-Manuel Fernández-Carreira; Carmen Rosa Fernández-Alvarez; Rafael Venta Obaya; Marìa Dolores Macías-Robles; Alvaro González-Franco; Maria Ana Arias Garcìa
Journal:  Haematologica       Date:  2003-09       Impact factor: 9.941

8.  Effect of blood collection and processing on radioimmunoassay results for apolipoprotein A-I in plasma.

Authors:  S A Brown; C E Rhodes; K Dunn; A M Gotto; W Patsch
Journal:  Clin Chem       Date:  1988-05       Impact factor: 8.327

9.  Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology.

Authors:  Mary Cushman; Albert W Tsai; Richard H White; Susan R Heckbert; Wayne D Rosamond; Paul Enright; Aaron R Folsom
Journal:  Am J Med       Date:  2004-07-01       Impact factor: 4.965

10.  Cardiovascular risk factors and venous thromboembolism: a meta-analysis.

Authors:  Walter Ageno; Cecilia Becattini; Timothy Brighton; Rita Selby; Pieter W Kamphuisen
Journal:  Circulation       Date:  2007-12-17       Impact factor: 29.690

View more
  19 in total

1.  Association of Apo(a)isoform size with dyslipoproteinemia in male venous thrombosis patients.

Authors:  Marian C Cheung; John J Albers; Hal Kennedy; Hiroshi Deguchi; Darlene J Elias; Patricia M Averell; John H Griffin; Santica M Marcovina
Journal:  Clin Chim Acta       Date:  2010-05-19       Impact factor: 3.786

Review 2.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

3.  Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis.

Authors:  Keattiyoat Wattanakit; Pamela L Lutsey; Elizabeth J Bell; Heather Gornik; Mary Cushman; Susan R Heckbert; Wayne D Rosamond; Aaron R Folsom
Journal:  Thromb Haemost       Date:  2012-07-10       Impact factor: 5.249

Review 4.  Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis.

Authors:  Eun Ji Chung; Matthew Tirrell
Journal:  Adv Healthc Mater       Date:  2015-06-17       Impact factor: 9.933

5.  Extrahepatic high-density lipoprotein receptor SR-BI and apoA-I protect against deep vein thrombosis in mice.

Authors:  Alexander Brill; Ayce Yesilaltay; Simon F De Meyer; Janka Kisucka; Tobias A Fuchs; Olivier Kocher; Monty Krieger; Denisa D Wagner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-31       Impact factor: 8.311

6.  Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women.

Authors:  B M Everett; R J Glynn; J E Buring; P M Ridker
Journal:  J Thromb Haemost       Date:  2009-01-24       Impact factor: 5.824

7.  A randomized trial of rosuvastatin in the prevention of venous thromboembolism.

Authors:  Robert J Glynn; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Paul M Ridker
Journal:  N Engl J Med       Date:  2009-03-29       Impact factor: 91.245

Review 8.  Targeting and therapeutic peptides in nanomedicine for atherosclerosis.

Authors:  Eun Ji Chung
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-27

9.  Inflammatory plasma markers and risk for venous thromboembolism.

Authors:  Signy V Sveinsdottir; Peter J Svensson; Gunnar Engström
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 10.  Emerging views of statin pleiotropy and cholesterol lowering.

Authors:  Dongbo Yu; James K Liao
Journal:  Cardiovasc Res       Date:  2022-01-29       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.